CDX2 and colorectal carcinoma: For validation studies in cellulo (CRC cell lines), in vivo (murine xenografts) and ex vivo (a “living biobank” of patient-derived organoids [PDOs]), we prioritized models with contrasting CDX2 expression (high vs. low, as determined based on a threshold that was determined using StepMiner81; see STAR Methods): CDX2-low (target phenotype) and CDX2-high (negative control).